6.
Palomero J, Vegliante M, Eguileor A, Rodriguez M, Balsas P, Martinez D
. SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. Leukemia. 2015; 30(7):1596-9.
DOI: 10.1038/leu.2015.355.
View
7.
Balsas P, Palomero J, Eguileor A, Rodriguez M, Vegliante M, Planas-Rigol E
. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017; 130(4):501-513.
DOI: 10.1182/blood-2017-04-776740.
View
8.
Balsas P, Veloza L, Clot G, Sureda-Gomez M, Rodriguez M, Masaoutis C
. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021; 138(22):2202-2215.
PMC: 8641098.
DOI: 10.1182/blood.2020010527.
View
9.
Kuo P, Jatiani S, Rahman A, Edwards D, Jiang Z, Ahr K
. SOX11 augments BCR signaling to drive MCL-like tumor development. Blood. 2018; 131(20):2247-2255.
PMC: 5958658.
DOI: 10.1182/blood-2018-02-832535.
View
10.
Liu C, Jin Y, Fan Z
. The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer. Front Oncol. 2021; 11:698023.
PMC: 8446599.
DOI: 10.3389/fonc.2021.698023.
View
11.
Hayes J, Dinkova-Kostova A, Tew K
. Oxidative Stress in Cancer. Cancer Cell. 2020; 38(2):167-197.
PMC: 7439808.
DOI: 10.1016/j.ccell.2020.06.001.
View
12.
Harris I, DeNicola G
. The Complex Interplay between Antioxidants and ROS in Cancer. Trends Cell Biol. 2020; 30(6):440-451.
DOI: 10.1016/j.tcb.2020.03.002.
View
13.
Poljsak B, Milisav I
. The Role of Antioxidants in Cancer, Friends or Foes?. Curr Pharm Des. 2019; 24(44):5234-5244.
DOI: 10.2174/1381612825666190123112647.
View
14.
Wang S, Davis S, Cerhan J, Hartge P, Severson R, Cozen W
. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis. 2006; 27(9):1828-34.
DOI: 10.1093/carcin/bgl013.
View
15.
Bur H, Haapasaari K, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P, Marin K
. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology. 2014; 65(3):319-27.
DOI: 10.1111/his.12389.
View
16.
Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D
. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2005; 107(1):257-64.
DOI: 10.1182/blood-2005-05-2091.
View
17.
Navarro A, Clot G, Martinez-Trillos A, Pinyol M, Jares P, Gonzalez-Farre B
. Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017; 102(9):e360-e363.
PMC: 5685223.
DOI: 10.3324/haematol.2016.160374.
View
18.
Nadeu F, Martin-Garcia D, Clot G, Diaz-Navarro A, Duran-Ferrer M, Navarro A
. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020; 136(12):1419-1432.
PMC: 7498364.
DOI: 10.1182/blood.2020005289.
View
19.
Scott D, Abrisqueta P, Wright G, Slack G, Mottok A, Villa D
. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. J Clin Oncol. 2017; 35(15):1668-1677.
PMC: 5455765.
DOI: 10.1200/JCO.2016.70.7901.
View
20.
Queiros A, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A
. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell. 2016; 30(5):806-821.
PMC: 5805090.
DOI: 10.1016/j.ccell.2016.09.014.
View